Trials of melatonin as COVID-19 supplementary treatment to run for 4 months -Duterte

The Department of Science and Technology (DOST) has approved a P9.8-million project to support the clinical trials on the use of melatonin as supplementary treatment for COVID-19 patients with pneumonia, President Rodrigo Duterte said Monday.

In his weekly report to Congress, Duterte said the project will be conducted by a team from the Manila Doctors Hospital for four months and will involve 350 patients.

“Initial studies have shown that melatonin improved outcomes in patients admitted to the Manila Doctors Hospital with COVID-19 pneumonia and high-risk features,” he said.

“Results of the project are expected to contribute to national and international guidelines on life-saving drugs and therapy that can impact mortality in COVID-19 pneumonia patients.”

According to the DOST, the sleep-aid supplement melatonin is also known for its anti-inflammation, anti-oxidation and immune-enhancing effects which may help alleviate acute respiratory distress caused by viral infections such as COVID-19.

As of Monday, the Philippines reported 26,420 COVID-19 cases, with 1,098 deaths and 6,252 recoveries. -NB, GMA News